他莫昔芬是一種廣泛應(yīng)用于治療激素敏感型乳腺癌的抗雌激素類藥物。臨床研究和動(dòng)物實(shí)驗(yàn)已經(jīng)證實(shí)他莫昔芬可以誘發(fā)非酒精性脂肪性肝病(NALFD)。目前認(rèn)為他莫昔芬誘發(fā)NALFD的機(jī)制主要包括脂肪酸的合成、脂肪酸的β氧化、三酰甘油轉(zhuǎn)運(yùn)異常以及雌激素拮抗作用。對他莫昔芬誘發(fā)NAFLD及其發(fā)病機(jī)制的研究現(xiàn)狀進(jìn)行了綜述。

Tamoxifen is an anti-estrogen drug widely used for the treatment of hormone-sensitive breast cancer. Clinical research and animal studies have confirmed that tamoxifen can induce nonalcoholic fatty liver disease (NALFD). So far, the pathogenesis of NALFD induced by tamoxifen include synthesis of aliphatic acid, β-oxidation of aliphatic acid, abnormal export of triacylglycerol, and inhibition of estrogens. The NAFLD induced by tamoxifen and its pathogenesis are reviewed in this paper.

北京市教育委員會(huì)科技發(fā)展計(jì)劃面上項(xiàng)目(KM201510025017)